Back

A randomized, double-blind, placebo-controlled, mechanistic trial on the safety, tolerability and pharmacodynamics of ninerafaxstat in patients with angina and chronic coronary syndrome

31 August 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in coronary artery disease: from bench to bedside (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Antti Saraste

Turku University Hospital, Turku (Finland)

8 More presentations in this session

Presentation thumbnail
Platelet membrane coated r-SAK to improve thrombolytic efficacy by targeting thrombus
Miss R. Hua (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
AtheroVax: a peptide vaccine with a therapeutic effect in animal model of chronic inflammation
Professor E. Ramacciotti (Santo Andre, BR)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter 2 inhibitor attenuates left ventricular dysfunction in post-myocardial infarction in rats via reducing cardiac mitochondrial impairment
Doctor C. Maneechote (Chiang Mai, TH)
Abstract Slides Video
Presentation thumbnail
A new free radical scavenger, resorcimoline, prevents ischaemia/reperfusion injury in the heart
Doctor K. Ueno (Oita, JP)
Abstract Slides Video
Presentation thumbnail
Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy
Professor R. Storey (Sheffield, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in coronary artery disease: from bench to bedside (1)

The Event

Event poster

ESC Congress 2024

31 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
A multicenter, randomized, double-blind, placebo-controlled, parallel group study on the safety and efficacy of istaroxime for pre-cardiogenic shock
thumbnail
Congress Presentation
The ARAMIS trial - Allopurinol in patients with Refractory Angina to iMprove Ischemic Symptoms
thumbnail
Congress Presentation
Angiogenic gene therapy for refractory angina: results of the epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (EXACT) phase 2 trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources